Simultaneous activation of PPARα, PPARδ and PPARγ by a single compound is being pursued to treat the multiple defects associated with insulin resistance, type 2 diabetes and the metabolic syndrome [16]. The gene discussed is PPARA; the disease is type 2 diabetes mellitus.